Skip to Content

Join the 'Sonidegib' group to help and get support from people like you.

Sonidegib News

Treatment Costs Can Be Another Blow to Cancer Patients

Posted 27 Jul 2017 by Drugs.com

THURSDAY, July 27, 2017 – The emotional and physical costs of cancer can be staggering. But the financial side of cancer is also a great burden, with many patients in the United States struggling to pay for treatment, new research reveals. "The current health law has greatly improved access to meaningful health coverage for cancer patients, survivors and all those with chronic diseases," Chris Hansen, president of the American Cancer Society Cancer Action Network, said in a network news release. "Yet costs remain a challenge for those facing cancer. Our country and our lawmakers should come together to find bipartisan solutions that begin to address patient costs without sacrificing the quality of coverage," he urged. Researchers surveyed financial navigators at 11 hospitals in nine states. Financial navigators – typically trained social workers or nurses – help cancer patients ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Breast Cancer, Prostate Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Lung Cancer, Colorectal Cancer, Gleevec, Non-Small Cell Lung Cancer, Brain Tumor, Anastrozole, Letrozole, Tarceva, Megestrol

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Prostate Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Tretinoin, Lupron Depot, Femara, Lung Cancer, Colorectal Cancer, Rituxan, Gleevec, Isotretinoin

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Tretinoin, Lupron Depot, Femara, Lung Cancer, Colorectal Cancer, Rituxan, Gleevec, Isotretinoin, Votrient

FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma

Posted 26 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. Skin cancer is the most common cancer and basal cell carcinoma accounts for approximately 80 percent of non-melanoma skin cancers. Basal cell carcinoma starts in the top layer of the skin (called the epidermis) and usually develops in areas that have been regularly exposed to the sun and other forms of ultraviolet radiation. According to the National Cancer Institute, the number of new cases of non-melanoma skin cancer appears to be increasing every year. Locally advanced basal cell skin cancer refers to basal cancers that have not spread to other parts of the body, but cannot be curatively treated with local treatments, ... Read more

Related support groups: Basal Cell Carcinoma, Skin Cancer, Sonidegib, Odomzo

New Skin Cancer Drug Odomzo Approved by FDA

Posted 26 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – A new drug to treat the most common form of skin cancer has been approved by the U.S. Food and Drug Administration. Odomzo (sonidegib) was cleared to treat locally advanced basal cell carcinoma in patients who cannot undergo surgery or radiation therapy, or whose skin cancer has returned after surgery or radiation therapy. Skin cancer is the most common type of cancer, and basal cell carcinoma accounts for about 80 percent of non-melanoma skin cancers. Locally advanced basal cell skin cancer has not spread to other parts of the body, but cannot be cured with surgery or radiation. Odomzo is a once-a-day pill designed to suppress a molecular pathway that is active in basal cell cancers, according to the FDA. The drug's approval was based on a clinical trial that included 66 patients who took 200 milligrams (mg) of Odomzo a day and 128 patients who took 800 mg a ... Read more

Related support groups: Basal Cell Carcinoma, Skin Cancer, Sonidegib, Odomzo

Odomzo Approved for Recurring Basal Cell Carcinoma

Posted 26 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat basal cell carcinoma skin cancer that has returned despite surgery or radiation. The treatment is sanctioned for people who are not candidates for additional surgery or radiation. Basal cell carcinoma accounts for about 80 percent of skin cancers that are not melanoma, a more deadly form of the disease. Basal cell starts in the top layer of skin, usually in areas that are most exposed to the sun, the agency said Friday in a news release. The once-daily pill is designed to inhibit a process that promotes the growth of cancerous lesions. The drug's label includes a boxed warning that it may cause death or severe birth defects in a growing fetus. Women who may become pregnant should verify pregnancy status before taking the drug. And both males and females who take Odomzo are ... Read more

Related support groups: Basal Cell Carcinoma, Skin Cancer, Sonidegib, Odomzo

Ask a Question

Further Information

Related Condition Support Groups

Basal Cell Carcinoma

Related Drug Support Groups

Odomzo

Sonidegib Patient Information at Drugs.com